Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
PHASE3
60 participants
INTERVENTIONAL
2022-03-01
2024-04-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
What Are the Determinant Factors of Ceasing Anti-seizure Medication in Infants With Neonatal Seizures?
NCT06211192
Effect of Magnesium Supplementation for Children With Drug Resistant Idiopathic Epilepsy
NCT02982824
Pilot Study of Bumetanide for Newborn Seizures
NCT00830531
the Safety and Efficacy of N-acetyl Cysteine in Children With Drug-Resistant Epilepsy
NCT05485558
Epileptic Syndromes in Infants and Early Childhood
NCT06223334
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Lacosamide
Lacosamide will be given.
Lacosamide
lacosamide will be given
Phenobarbitone
Phenobarbital will be given
Phenobarbital
phenobarbital will be given
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Lacosamide
lacosamide will be given
Phenobarbital
phenobarbital will be given
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
28 Days
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Sherief Abd-Elsalam
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Sherief Abd-Elsalam
ass prof tropical medicine
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
abeer salamah, lecturer
Role: PRINCIPAL_INVESTIGATOR
Kafrelsheikh University
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Kafrelsheikh University
Tanta, Kafrelsheikh, Egypt
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
abeer salamah, lecturer
Role: primary
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
abeer ped neurology
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.